Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped up before the market opened on Tuesday . The stock had previously closed at $48.24, but opened at $51.6950. Zealand Pharma A/S shares last traded at $51.6950, with a volume of 102 shares.

Analyst Upgrades and Downgrades

ZLDPF has been the topic of a number of recent research reports. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Zacks Research downgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The firm has a fifty day simple moving average of $46.45 and a 200 day simple moving average of $48.59. The company has a market cap of $3.70 billion, a price-to-earnings ratio of 8.57 and a beta of 0.88.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.